Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.-MedSci.cn

Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.

Hassan, R; Butler, MO; Oh, DY; O'Cearbhaill, RE; MacMullen, L; Jeter, E; Guha, U; Muzithras, VP; Zikaras, K; Johnson, ML; Tanyi, JL; Ghafoor, A; Tighe, R; Smalley, M; Quintas-Cardama, A; Hong, DS

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务